FENC LAWSUIT ALERT: Levi & Korsinsky Notifies Fennec Pharmaceuticals Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
PR Newswire
NEW YORK
,
Feb. 17, 2022
/PRNewswire/ — Levi & Korsinsky, LLP notifies investors in
Fennec Pharmaceuticals Inc.
(“Fennec” or the “Company”) (NASDAQ: FENC) of a class action securities lawsuit.
CLASS DEFINITION:
The lawsuit seeks to recover losses on behalf of Fennec investors who were adversely affected by alleged securities fraud between
May 28, 2021
and
November 26, 2021
. Follow the link below to get more information and be contacted by a member of our team:
FENC
investors may also contact
Joseph E. Levi, Esq.
via email
at [email protected] or
by telephone at (212) 363-7500.
CASE DETAILS:
The filed complaint alleges that defendants made false statements and/or concealed that: (i) Fennec had not successfully remediated, and overstated its efforts to remediate, issues with the manufacturing facility of its drug product manufacturer for PEDMARK, a new compound developed to reduce the incidence of hearing loss in children undergoing chemotherapy; (ii) as a result, the Food and Drug Administration likely to approve the Resubmitted Pedmark New Drug Application (“NDA”); (iii) accordingly, the regulatory and commercial prospects of the Resubmitted Pedmark NDA were overstated; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.
WHAT’S NEXT?
If you suffered a loss in Fennec during the relevant time frame, you have until
April 11, 2022
to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
NO COST TO YOU:
If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees.
There is no cost or obligation to participate.
WHY LEVI & KORSINSKY:
Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in
the United States
.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY
10006
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com
View original content to download multimedia:
https://www.prnewswire.com/news-releases/fenc-lawsuit-alert-levi–korsinsky-notifies-fennec-pharmaceuticals-inc-investors-of-a-class-action-lawsuit-and-upcoming-deadline-301484730.html
SOURCE Levi & Korsinsky, LLP
